RNA Sequencing Provides Evidence for Pathogenicity of a Novel CHEK2 Splice Variant (C.1009-7T>G)

참고문헌 (10)

1. "National Cancer Registration Program, Annual report of cancer statistics in Korea in 2018" (2021)[URL]
2. Wu Y, "A comprehensive evaluation of CHEK2 germline mutations in men with prostate cancer", Prostate, 78, pp.607~615 (2018)
3. de Bono J, "Olaparib for metastatic castration-resistant prostate cancer", N Engl J Med, 382, pp.2091~2102 (2020)
4. Delimitsou A, "Functional characterization of CHEK2 variants in a Saccharomyces cerevisiae system", Hum Mutat, 40, pp.631~648 (2019)
5. Cybulski C, "CHEK2 is a multiorgan cancer susceptibility gene", Am J Hum Genet, 75, pp.1131~1135 (2004)
6. Richards S, "Standards and guidelines for the interpretation of sequence variants : a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology", Genet Med, 17, pp.405~424 (2015)
7. Jian X, "In silico prediction of splice-altering single nucleotide variants in the human genome", Nucleic Acids Res, 42, pp.13534~13544 (2014)
8. Brnich SE, "Recommendations for application of the functional evidence PS3", BS3 criterion using the ACMG, Genome Med, pp.2019, 12[DOI]
9. Stolarova L, "CHEK2 germline variants in cancer predisposition : stalemate rather than checkmate", Cells, 9, pp.2675~ (2020)
10. Anna A, "Splicing mutations in human genetic disorders: examples, detection, and confirmation", J Appl Genet, 59, pp.253~268 (2018)

관련 논문AI추천